shutterstock_1472976248_siberian_art

Siberian Art / Shutterstock.com

4 September 2020BiotechnologyRory O'Neill

LSPN Connect: Protecting biologics at home and abroad

Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

LSPN 19: Mayo has led us down the rabbit hole, says lawyer

26 April 2019 There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.

More on this story

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

LSPN 19: Mayo has led us down the rabbit hole, says lawyer

26 April 2019 There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.

More on this story

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

22 October 2019 While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

LSPN 19: Mayo has led us down the rabbit hole, says lawyer

26 April 2019 There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott